zonisamide (Zonegran)

12/01/2004 - "We conclude that zonisamide is highly effective for partial seizures and generalized seizures, and that there appears to be no decrease in efficacy with long-term use."
12/01/2004 - "Zonisamide was highly effective for treating partial seizures, with 70% of patients reporting improvement. "
01/01/1998 - "Zonisamide dramatically reduced the amount of myoclonias and generalized seizures. "
01/01/2014 - "At 5 years of age, addition of zonisamide further reduced the frequency of seizure episodes, but failed to achieve complete control of seizures. "
06/01/1988 - "After zonisamide therapy was initiated, both had a marked decrease in seizure frequency and significant improvement of functioning. "

01/01/2008 - "These results are similar to the findings of Japanese studies suggesting that long-term use of adjunctive zonisamide therapy may be beneficial for treating mentally retarded, multiple handicapped patients with highly refractory childhood-onset epilepsy."
01/01/2013 - "Adjunctive zonisamide therapy was demonstrated to be beneficial for multiple-disabled patients with refractory childhood-onset epilepsy. "
11/01/2012 - "Based on these results, zonisamide monotherapy is effective in some dogs with idiopathic epilepsy."
03/01/2007 - "Zonisamide (ZNS) is a new AED effective in the treatment of refractory epilepsy and since it is only prescribed in polytherapy regimens, its interactions with other AEDs is of particular importance. "
04/01/1998 - "Zonisamide (ZNS) is effective in animal models of epilepsy and epileptic patients. "

08/01/2013 - "Adjunctive zonisamide treatment was shown to be effective and well tolerated in pediatric patients with partial epilepsy. "
02/01/2013 - "Zonisamide seems to be effective and safe in focal epilepsy. "
01/01/2012 - "The clinical efficacy of adjunctive zonisamide therapy has been established in four pivotal, phase III, randomized, double-blind, placebo-controlled trials, which together included approximately 850 patients, aged 12-77 years, with refractory partial epilepsy. "
01/01/2015 - "The safety and long-term efficacy of zonisamide as adjunctive therapy for focal epilepsy."
04/01/2014 - "To investigate the safety/tolerability and efficacy of long-term adjunctive zonisamide and its impact on growth and development in children (6-18 years) with partial epilepsy. "

12/01/2009 - "Although further study of zonisamide is warranted, high-dose zonisamide can be effective and safe in some infants with newly diagnosed West syndrome."
09/01/2000 - "We determined that zonisamide was effective in three epileptic infants with hypsarrhythmia. "
05/01/1999 - "[Efficacy of zonisamide in West syndrome]."
04/01/1999 - "We determined the efficacy of and tolerability to zonisamide (ZNS) in newly diagnosed patients with infantile spasms. "
09/01/1997 - "We determined the short-term efficacy of zonisamide (ZNS) monotherapy in newly diagnosed patients with infantile spasms (IS). "

04/01/2010 - "The addition of zonisamide at 25-50 mg/day to currently used antiparkinsonian drugs significantly improved cardinal symptoms in patients with advanced Parkinson's disease. "
01/01/2014 - "The anti-epileptic agent zonisamide (ZNS) has been shown to exert protective effects in neurotoxin-based mouse models of Parkinson disease. "
09/01/2009 - "A multicentered, randomized, double-blind, placebo-controlled study conducted in Japan suggested that zonisamide, as an add-on treatment, has efficacy in treating motor symptoms in patients with Parkinson's disease. "
09/01/2007 - "A multicentered, randomized, double-blind, placebo-controlled study conducted in Japan provided data suggesting that zonisamide, as an add-on treatment, has efficacy in treating motor symptoms in patients with Parkinson's disease (PD). "
08/15/2012 - "The current study demonstrates the effects of zonisamide on astrocyte cultures and two 6-hydroxydopamine-induced models of Parkinson's disease. "